Indegene Limited

Indegene Limited

Indegene Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Indegene Limited

Indegene Limited has announced the resignation of Mr. Mark Francis Dzialga as a Non-Executive Director of the company, effective October 29, 2026, due to the sale of his entire shareholding in the company.

Indegene Limited

Indegene Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance under Regulation 74(5) for the quarter ended September 30, 2026.

Indegene Limited

Indegene Limited has informed the Exchange regarding allotment of 16110 securities pursuant to ESOP Scheme 2020 of the Company.

Indegene Limited

Indegene Limited has announced the success of its Indegene Digital Summit 2026, which featured keynotes, panels, and presentations from industry leaders, policymakers, and AI innovators. The event showcased Indegene's AI and platform capabilities, and highlighted its growing influence as a strategic partner, AI innovator, and industry convenor.

Indegene Limited

Indegene Limited has informed the Exchange about the schedule of its Q2 FY27 Earnings Call, to be held on 30th October 2026, 8:00 AM IST, where senior management will interact with investors on the company's Q2 FY27 earnings.

Indegene Limited

Indegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the finalization and approval of financial results for the quarter and half year ended September 30, 2026.

Indegene Limited

Indegene Limited has informed the Exchange regarding a press release dated September 23, 2026, titled 'From Promise to Performance: Life Sciences Leaders Focus on Operationalizing AI to Deliver Enterprise Outcomes at Indegene Digital Summit 2026'. The press release highlights the company's eighth edition of the Indegene Digital Summit, which brought together 200+ leaders from across the global life sciences ecosystem for discussions on the future of life sciences and the role of leaders in turning bold ideas into action.

Indegene Limited

Indegene Limited has informed the Exchange about the amalgamation/merger of its indirect wholly owned subsidiaries in Germany, Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH, with the latter becoming the surviving entity and changing its name to Indegene Healthcare Germany GmbH. The merger is part of an internal reorganization and does not have any material impact on the business operations, shareholding pattern, or financial position of Indegene Limited.

Indegene Limited

Indegene Limited has informed the Exchange about a scheduled investor and analyst meeting on September 11, 2026, in Bengaluru, Karnataka, India.

Indegene Limited

Indegene Limited has informed the Exchange about the preliminary approval of a proposed class action settlement against its wholly-owned overseas subsidiary, Indegene, Inc., before the U.S. District Court, District of New Jersey. The settlement remains subject to completion of the notice and claims process and final approval by the Court.

Indegene Limited

Indegene Limited has informed the Exchange about the schedule of an investor/analyst meeting to be held on August 24 and 25, 2026, for various investors and analysts. The meeting will be held online or in-person in Bengaluru, and no unpublished price-sensitive information will be shared.

Indegene Limited

Indegene Limited has informed the Exchange about the pendency of litigation involving its wholly-owned subsidiary, Indegene, Inc., in the U.S. District Court, District of New Jersey. The lawsuit relates to alleged violations of the U.S. Telephone Consumer Protection Act, 1991. The parties have concluded negotiations on the definitive settlement agreement, subject to execution by the relevant parties and approval of the U.S. District Court.

Indegene Limited

Indegene Limited has held its 28th Annual General Meeting through video conference, with the Chairman and Directors introducing themselves and confirming the quorum is present.

Indegene Limited

Indegene Limited has informed the Exchange regarding Change in Director(s) of the company. Ms. Jill Mary De Simone has been appointed as an Independent Director for a term of 3 years.

Indegene Limited

Indegene Limited has submitted the Exchange a copy of the Scrutinizers report of Annual General Meeting held on August 13, 2026, and informed the Exchange regarding voting results.

Indegene Limited

Indegene Limited has informed the Exchange about a scheduled investor/analyst meeting on August 19, 2026, in Mumbai, where no unpublished price-sensitive information will be shared.

Indegene Limited

Indegene Limited has held its 28th Annual General Meeting (AGM) on August 13, 2026, through video conferencing. The meeting was attended by the Chairman, Executive Director, and Chief Executive Officer, along with other key management personnel and statutory auditors. The proceedings were video recorded and webcast on the National Depository System Limited's website. The company secretary briefed members on the e-voting process and the scrutinizer was appointed to ensure a fair and transparent process.

Indegene Limited

Indegene Limited has informed the Exchange about Schedule of meet for Investor / Analyst meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Indegene Limited

Indegene Limited has informed the Exchange about a scheduled meeting with investors and analysts.